The accumulation of amyloid-beta in the brain is believed to be a culprit behind neurodegeneration, but the underlying mechanism of the buildup is not yet clear. The biopharma industry’s endeavor to develop drugs that target the protein has also suffered many setbacks.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,